1 asset in Liver Neuroendocrine Carcinoma
Therapeutic assets addressing Liver Neuroendocrine Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
Paltusotine Liver Neuroendocrine Carcinoma | Crinetics Pharmaceuticals Inc. | P3 | BB (66) |